Tennessee Valley Asset Management Partners Sells 638 Shares of Johnson & Johnson (NYSE:JNJ)

Tennessee Valley Asset Management Partners cut its stake in shares of Johnson & Johnson (NYSE:JNJ) by 19.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,604 shares of the company’s stock after selling 638 shares during the period. Tennessee Valley Asset Management Partners’ holdings in Johnson & Johnson were worth $377,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also modified their holdings of the company. Quarry LP bought a new stake in Johnson & Johnson in the second quarter worth about $49,000. Advisory Alpha LLC lifted its stake in shares of Johnson & Johnson by 6.8% during the 2nd quarter. Advisory Alpha LLC now owns 5,743 shares of the company’s stock worth $839,000 after acquiring an additional 367 shares during the last quarter. Birmingham Capital Management Co. Inc. AL boosted its holdings in Johnson & Johnson by 4.0% during the 2nd quarter. Birmingham Capital Management Co. Inc. AL now owns 43,076 shares of the company’s stock valued at $6,296,000 after acquiring an additional 1,644 shares during the period. Strategic Investment Solutions Inc. IL bought a new position in Johnson & Johnson in the 2nd quarter valued at $283,000. Finally, Brown Financial Advisors bought a new stake in shares of Johnson & Johnson during the second quarter worth $1,973,000. 69.55% of the stock is owned by institutional investors.

Insider Activity at Johnson & Johnson

In other news, Director Mark A. Weinberger acquired 1,000 shares of the business’s stock in a transaction dated Thursday, December 12th. The shares were acquired at an average cost of $147.22 per share, with a total value of $147,220.00. Following the completion of the acquisition, the director now owns 1,000 shares of the company’s stock, valued at approximately $147,220. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. 0.16% of the stock is owned by insiders.

Johnson & Johnson Stock Up 0.6 %

Shares of JNJ stock opened at $151.27 on Thursday. The stock’s fifty day moving average price is $147.76 and its 200 day moving average price is $156.13. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $168.85. The company has a market cap of $364.20 billion, a price-to-earnings ratio of 22.75, a price-to-earnings-growth ratio of 2.45 and a beta of 0.51.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.99 by $0.05. The firm had revenue of $22.52 billion for the quarter, compared to the consensus estimate of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.35%. The company’s revenue for the quarter was up 5.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.29 earnings per share. On average, research analysts expect that Johnson & Johnson will post 10.56 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be issued a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.28%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 74.59%.

Wall Street Analyst Weigh In

Several research analysts recently commented on JNJ shares. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 25th. Raymond James decreased their price target on shares of Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating for the company in a research note on Thursday, January 23rd. Bank of America reduced their price objective on Johnson & Johnson from $160.00 to $159.00 and set a “neutral” rating on the stock in a report on Thursday, January 23rd. Wolfe Research initiated coverage on Johnson & Johnson in a report on Friday, November 15th. They issued an “outperform” rating and a $190.00 target price for the company. Finally, Stifel Nicolaus decreased their price objective on Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating for the company in a report on Thursday, January 23rd. Nine equities research analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and an average price target of $170.44.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.